Table 4 Secondary outcomes in the intervention and control group (usual care)

SF-12, MCS score

44.4 (12.4), 23.4–59.8

14

49.0 (11.1), 35.7–65.6

11

Barthel index^a, median (IQR)

90.0 (70.0–100.0)

5

95.0 (66.3–100.0)

12

Chair rising test, median (IQR), seconds^b

16.0 (9.5–22.5)

6

20 (12.0–32.5)

6

Hand grip strength, kg^c

28.3 (13), 11–47

11

28.5 (15.7), 7–52

7

PTSS-10 score

27.4 (13.3)

15

25.8 (10.6)

12

Indication & strong indication for PTSD according PTSS-10, n (%)

9 (60.0)

15

6 (50.0)

12

PHQ-D (short form)

Minimal to moderate^ddepressive condition, n (%)

12 (80.0)

15

10 (83.3)

12

Moderately severe to severe depressive condition, n (%)

3 (20.0)

2 (16.7)

Strong and very strong mental symptom-related difficulty^ein daily and working life, n (%)

4 (26.7)

15

3 (25.0)

12

Panic attack during last four weeks, n (%)

4 (26.7)

15

3 (25.0)

12

HRQOL next of kin

SF-12, PCS score

48.7 (7.4), 37.5–57.0

10

53.1 (4.9), 46.5–58.0

4

SF-12, MCS score

38.5 (11.4), 12.5-50.3

10

47.3 (10.0), 34.0–57.8

4

Health care use (any visit to the following specialties), n (%)^f

15

12

General medicine

14 (93.3)

10 (83.3)

Internal medicine

9 (60.0)

7 (58.3)

Otolaryngology

5 (33.3)

9 (75.0)

Neurology

9 (60.0)

2 (16.6)

Dental medicine

7 (46.7)

3 (25.0)